The safety and efficacy of high dose ferric carboxymaltose in patients with chronic kidney disease: A single center study

about

The safety and efficacy of high dose ferric carboxymaltose in patients with chronic kidney disease: A single center study

Item

http://www.wikidata.org/entity/Q35830277

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

The safety and efficacy of hig ...... disease: A single center study

@ast

The safety and efficacy of hig ...... disease: A single center study

@en

type

Item

label

The safety and efficacy of hig ...... disease: A single center study

@ast

The safety and efficacy of hig ...... disease: A single center study

@en

prefLabel

The safety and efficacy of hig ...... disease: A single center study

@ast

The safety and efficacy of hig ...... disease: A single center study

@en

P1476

The safety and efficacy of hig ...... disease: A single center study

@en

P2093

A Parashar

http://www.w3.org/2001/XMLSchema#string

S Vikrant

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data

The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study.

A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.

Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.

FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.

A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients.

Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.

Iron therapy in chronic kidney disease: current controversies.

Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?

The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose.

P304

213-221

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/0971-4065.144421

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280327050

http://www.w3.org/2001/XMLSchema#string

P698

26199472

http://www.w3.org/2001/XMLSchema#string

P932

4495475

http://www.w3.org/2001/XMLSchema#string